Eurofins Scientific SE Share Price
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.50 EUR | +0.78% |
|
+1.16% | +11.38% |
| 06-30 | NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation |  |
| 06-04 | Eurofins Scientific SE acquired High North Laboratories. | CI |
| Market Cap | 12.15B 13.85B 11.25B 10.35B 19.58B 1,325B 19.96B 134B 52.58B 651B 52B 50.86B 2,248B | P/E 2026 * |
24.1x | P/E 2027 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 15.59B 17.77B 14.44B 13.28B 25.12B 1,701B 25.61B 172B 67.48B 835B 66.73B 65.27B 2,885B | EV / Sales 2026 * |
2.05x | EV / Sales 2027 * | 1.89x |
| Free-Float |
58.35% | Yield 2026 * |
1.11% | Yield 2027 * | 1.29% |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.78% | ||
| 1 week | +1.16% | ||
| Current month | +1.37% | ||
| 1 month | +8.46% | ||
| 3 months | +7.09% | ||
| 6 months | -4.95% | ||
| Current year | +11.38% |
| 1 week | 66.6 |  | 69.94 |
| 1 month | 61.44 | | 70.28 |
| Current year | 56.84 | | 74.32 |
| 1 year | 54.86 | | 74.32 |
| 3 years | 39.47 | | 74.32 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 31/12/1986 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 31/12/2014 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 30/09/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 31/12/1986 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 31/12/2014 |
Valérie Hanote
BRD | Director/Board Member | 60 | 31/12/1989 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-26 | Buy | 700 | 0.0004% | |||
| 04-18 | Fiscal year | Executive/Senior Manager | 700 | 0.0004% | ||
| 04-18 | Sell | Chief Financial Officer | 3,000 | 0.0016% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.78% | +1.16% | +14.69% | +17.32% | 13.78B | |
| +0.44% | +1.41% | +4.36% | +10.81% | 50.73B | |
| -1.57% | -3.18% | +383.82% | +593.37% | 39.73B | |
| -0.14% | +0.77% | +27.49% | -5.50% | 34.69B | |
| +1.76% | -1.78% | +21.44% | +53.38% | 33.21B | |
| -0.06% | -0.45% | +2.94% | +28.70% | 26.76B | |
| -1.93% | -1.01% | - | - | 16.8B | |
| -1.49% | -6.18% | +63.89% | +120.53% | 15.37B | |
| -0.97% | -2.83% | +10.35% | -33.29% | 12.85B | |
| -2.28% | -6.83% | +1,589.17% | +646.89% | 12.11B | |
| Average | -0.55% | -1.55% | +235.35% | +159.13% | 25.6B | |
| Weighted average by Cap. | -0.28% | -0.66% | +157.93% | +150.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.6B 8.66B 7.04B 6.48B 12.25B 829B 12.49B 83.89B 32.9B 407B 32.54B 31.83B 1,406B | 8.07B 9.21B 7.48B 6.88B 13.01B 881B 13.27B 89.13B 34.96B 433B 34.57B 33.81B 1,494B |
| Net income | 517M 589M 479M 440M 833M 56.38B 849M 5.7B 2.24B 27.69B 2.21B 2.16B 95.62B | 676M 771M 626M 576M 1.09B 73.78B 1.11B 7.46B 2.93B 36.23B 2.89B 2.83B 125B |
| Net Debt | 3.44B 3.92B 3.19B 2.93B 5.55B 376B 5.66B 38B 14.9B 184B 14.74B 14.41B 637B | 3.08B 3.52B 2.86B 2.63B 4.97B 337B 5.07B 34.05B 13.35B 165B 13.21B 12.92B 571B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/07/26 | €69.50 | +0.78% | 151,866 |
| 10/07/26 | €68.96 | +0.23% | 233,361 |
| 09/07/26 | €68.80 | +2.59% | 280,414 |
| 08/07/26 | €67.06 | -2.70% | 226,836 |
| 07/07/26 | €68.92 | +0.32% | 205,550 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
